09:07 AM EST, 03/03/2026 (MT Newswires) -- Tempus AI ( TEM ) and Merck ( MRK ) said Tuesday they are collaborating to accelerate the discovery and development of artificial intelligence-driven precision medicine biomarkers.

Under the agreement, Merck ( MRK ) will use Tempus' de-identified data with Lens platform and Workspaces environment to conduct complex analysis on datasets to generate novel insights and accelerate drug development, the companies said.

Financial details were not disclosed.

Shares of Tempus AI ( TEM ) were down 3.4%, and Merck ( MRK ) shares were down over 1% in recent Tuesday premarket activity.